SOURCE: BioTech Medics, Inc.
IRVING, TX--(Marketwire - Nov 1, 2012) - BioTech Medics, Inc. (PINKSHEETS: BMCS) announced that it has signed a Letter of Interest for a $5 million U.S. cross-marketing licensing contract for its patented SHBAN Alcohol Free Persistent Hand & Body Sanitizer with LifeBionix, Inc. The final terms of the agreement are expected to be disclosed before yearend. The proposed agreement includes cash, dividends and ongoing royalties over a five-year term commencing the end of the first quarter in 2013.
According to a just published GIA Research Report which mentions BioTech Medics: "The US market for Hand Sanitizers is primarily driven by continued rise in health awareness and increasing demand for non-alcoholic products. Private label brands continue to dominate the US Hand Sanitizers market. The US market for Hand Sanitizers is projected to reach US$226.3 million by 2018. Abundant resources and improving knowledge on Hand Care are presently driving the market for new found Hand Sanitizers and Hand Rubs."
SHBAN is superior to alcohol hand sanitizers because it is non-flammable. Alcohol hand sanitizers are a Class I fire hazard. Additionally, the Poison Control centers have reported over 22,000 children and adults with alcohol poisoning from ingesting alcohol gels. SHBAN is a green product. SHBAN is non-poisonous (when used as directed); yet powerful enough to kill most germs and inhibit the flu viruses. Independent tests have shown SHBAN's active ingredient inhibits the Swine H1N1 Influenza A and Avian H5N1 Influenza A viruses.
SHBAN's active ingredient is FDA approved as an antiseptic as well as an antimicrobial solution. SHBAN's active ingredient is persistent and has been clinically proven to last four hours unless you sweat or wash it off. SHBAN is gentle on hands. SHBAN can be used on a cotton swab in your nostrils. Studies have shown that 80% of viruses are inhaled through the nostrils. SHBAN is available online: www.shban.com.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties; actual results could differ materially from those expressed. The FDA has not evaluated the SHBAN statements above. SHBAN is not intended to diagnose, treat or cure any disease.